1. bookVolume 27 (2019): Issue 2 (April 2019)
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

Systemic interleukins levels in community-acquired pneumonia and their association with adverse outcomes

Published Online: 02 May 2019
Page range: 189 - 198
Received: 04 Dec 2018
Accepted: 03 Mar 2019
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Abstract

Introduction: Community-acquired pneumonia (CAP) is still one of the major causes of morbidity and mortality worldwide. Pro-inflammatory and anti-inflammatory interleukins have been studied to elucidate the role that inflammation plays in its pathogenesis. The aim of this study is to investigate inflammation in CAP, by analyzing in dynamic, serum levels of six interleukins (IL) and their predictive value regarding adverse outcomes.

Materials and methods: Forty adult patients with CAP, admitted in the Teaching Hospital of Infectious Diseases, Cluj-Napoca, Romania from December 2015 to February 2017, were enrolled in this study. Serum levels of pro-inflammatory: IL1β, TNF-α, IL-6, anti-inflammatory: IL-10 and IL-4, along with IL-17A were analyzed in dynamic, on day 1 and day 4.The receiver – operator curves (ROC) were used to analyze the outcome prediction of IL.

Results: Serum levels of IL-1β, IL-6, TNF-α and IL-10 have decreased significantly in dynamic, while IL-4 increases. IL-17A has acted like a pro-inflammatory cytokine. We have found a correlation between IL-6 and IL-10 (r=0.429, p=0.000), IL-6 and IL-17A (r=0.295, p=0.008) and IL-10 and IL-17A (r=0.475, p=0.000). Out of 40 patients, 9 had adverse outcomes, consisting in 9 relapses from which 1 died. IL-6 discriminates alone between adverse and favorable outcomes. With multivariate analysis and multiple regression of all combined IL, we have found that there is a predictive model regarding adverse outcomes.

Conclusion: IL-10 and IL-17A behave like pro-inflammatory cytokines. IL-6 is a predictive marker for adverse outcomes alone. All IL studied together have an impact on adverse outcomes.

Keywords

1. Antunes G, Evans S, Lordan J, Frew A. Systemic cytokines levels in community-acquired pneumonia and their association with disease severity. Eur Respir J 2002;20:990-995. DOI: 10.1183/09031936.02.0029510210.1183/09031936.02.0029510212412694Open DOISearch in Google Scholar

2. Community-Acquired Pneumonia (CAP): Practice Essentials, Overview, Etiology of Community-Acquired Pneumonia [Online]. [2017] [cited 29 April 2018]; Available from: URL: https://emedicine.medscape.com/article/234240-overviewSearch in Google Scholar

3. Bordon J, Aliberti S, Fernandez-Botran R, Uriarte S, Rane M, Duvvuri P, et al. Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia. Int J Infect Dis 2013;17(2):e76-e83. DOI: 10.1016/j.ijid.2012.06.00610.1016/j.ijid.2012.06.00623069683Open DOISearch in Google Scholar

4. Fernandez-Botran R, Wiemken T, Kelley R, Peyrani P, Bordon J, Cavallazzi R, et al. Analysis of the local and systemic cytokine response profiles in patients with community-acquired pneumonia. Relationship with disease severity and outcomes. Univ Louisville J Respir 2017;1(3):13-20. DOI: 10.18297/jri/vol1/iss3/5/10.18297/jri/vol1/iss3/5/Search in Google Scholar

5. Endeman H, Meijvis S, Rijkers G, van Velzen-Blad H, van Moorsel C, Grutters J, et al. Systemic cytokine response in patients with community-acquired pneumonia. Eur Respir J 2011;37(6):1431-1438. DOI: 10.1183/09031936.0007441010.1183/09031936.0007441020884746Open DOISearch in Google Scholar

6. Wang RS, Jin HX, Shang SQ, Liu XY, Chen SJ, Jin ZB. Associations of IL-2 and IL-4 Expression and Polymorphisms with the Risks of Mycoplasma pneumoniae Infection and Asthma in Children. Arch Bronconeumol 2015;51(11):571-8. DOI: 10.1016/j.arbres.2014.11.00410.1016/j.arbres.2014.11.00425747600Search in Google Scholar

7. Paats M, Bergen I, Hanselaar W, Groeninx van Zoelen E, Hoogsteden H, Hendriks R, et al. Local and systemic cytokine profiles in nonsevere and severe community-acquired pneumonia. Eur Respir J 2013;41(6):1378-85. DOI: 10.1183/09031936.0006011210.1183/09031936.0006011223258791Open DOISearch in Google Scholar

8. Lorè N, Bragonzi A, Cigana C. The IL-17A/IL-17RA axis in pulmonary defence and immunopathology. Cytokine Growth Factor Rev 2016;30:19-27. DOI: 10.1016/j.cytogfr.2016.03.00910.1016/j.cytogfr.2016.03.00927033174Search in Google Scholar

9. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Dean NC, Whitney CG, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis 2007;44:S27-S72. DOI: 10.1086/51115910.1086/511159710799717278083Open DOISearch in Google Scholar

10. Eldaboosy SA, Halima KM, Shaarawy AT, Kanany HM, Elgamal EM, El-Gendi AA, et al. Comparison between CURB-65, PSI, and SIPF scores as predictors of ICU admission and mortality in community-acquired pneumonia. The egyptian journal of critical care medicine 2015;3(2):37-44. DOI: 10.1016/j.ejccm.2015.10.00110.1016/j.ejccm.2015.10.001Search in Google Scholar

11. [Online]. 2018 [cited 26 July 2018]. Available from: URL: https://lifeinthefastlane.com/wp-content/uploads/2010/07/etg-smartcop.Search in Google Scholar

12. Bone R, Balk R, Cerra F, Dellinger R, Fein A, Knaus W, et al. Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis. Chest 1992;101(6):1644-1655. DOI: 10.1378/chest.101.6.164410.1378/chest.101.6.16441303622Open DOISearch in Google Scholar

13. Gutiérrez F, Masiá M, Mirete C, Soldán B, Carlos Rodríguez J, Padilla S, et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect 2006;53(3):166-174. DOI: 10.1016/j.jinf.2005.11.00610.1016/j.jinf.2005.11.00616375972Open DOISearch in Google Scholar

14. Rozenbaum M, Mangen M, Huijts S, van der Werf T, Postma M. Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis. Vaccine 2015;33(28):3193-9. DOI: 10.1016/j.vaccine.2015.05.00110.1016/j.vaccine.2015.05.00125981488Open DOISearch in Google Scholar

15. Garau J, Baquero F, Pérez-Trallero E, Pérez J, Martín-Sánchez A, García-Rey C, et al. Factors impacting on length of stay and mortality of community-acquired pneumonia. Clin Microbiol Infect 2008;14(4):322-329. DOI: 10.1111/j.14690691.2007.01915.x10.1111/j.14690691.2007.01915.xOpen DOISearch in Google Scholar

16. Bacci M, Leme R, Zing N, Murad N, Adami F, Hinnig P, et al. IL-6 and TNF-α serum levels are associated with early death in community-acquired pneumonia patients. Braz J Med Biol Res 2015;48(5):427-432. DOI: 10.1590/1414-431X2014440210.1590/1414-431X20144402444566625714883Open DOISearch in Google Scholar

17. Puren A, Feldman C, Savage N, Becker P, Smith C. Patterns of Cytokine Expression in Community-Acquired Pneumonia. Chest 1995;107(5):1342-9. DOI: 10.1378/chest.107.5.134210.1378/chest.107.5.13427750329Open DOISearch in Google Scholar

18. Holub M, Lawrence D, Andersen N, Davidová A, Beran O, Marešová V, et al. Cytokines and Chemokines as Biomarkers of Community-Acquired Bacterial Infection. Mediators Inflamm 2013;2013:1-7. DOI: 10.1155/2013/19014510.1155/2013/190145365218923690657Open DOISearch in Google Scholar

19. Christ-Crain M, Opal S. Clinical review: The role of biomarkers in the diagnosis and management of community-acquired pneumonia. Crit Care 2010;14(1):203. DOI: 10.1186/cc815510.1186/cc8155287548020236471Open DOISearch in Google Scholar

20. Vasconcellos Â, Clarêncio J, Andrade D, Cardoso MA, Barral A, Nascimento-Carvalho CM. Systemic cytokines and chemokines on admission of children hospitalized with community-acquired pneumonia. Cytokine 2018;107:1-8. DOI: 10.1016/j.cyto.2017.11.00510.1016/j.cyto.2017.11.00529158121Open DOISearch in Google Scholar

21. Khattab A, El-Mekkawy M, Shehata A, Whdan N. Clinical study of serum interleukin-6 in children with community-acquired pneumonia. Gaz Egypt Paediatr Assoc 2018;66(2):43-48. DOI: 10.1016/j.epag.2018.03.00310.1016/j.epag.2018.03.003Open DOISearch in Google Scholar

22. Chai R, Liu B, Qi F. The significance of the levels of IL-4, IL-31 and TLSP in patients with asthma and/or rhinitis. Immunotherapy 2017;9(4):331-337. DOI: 10.2217/imt-2016-013110.2217/imt-2016-013128303765Open DOISearch in Google Scholar

23. Giuffrida M, Valero N, Mosquera J, Duran A, Arocha F, Chacín B, et al. Increased Systemic Cytokine/Chemokine Expression in Asthmatic and Non-asthmatic Patients with Bacterial, Viral or Mixed Lung Infection. Scand J Immunol 2017;85(4):280-290. DOI: 10.1111/sji.1253210.1111/sji.12532716957028168862Open DOISearch in Google Scholar

24. Medjo B, Atanaskovic-Markovic M, Nikolic D, Radic S, Lazarevic I, Cirkovic I, et al. Increased Serum Interleukin-10 but not Interleukin-4 Level in Children with Mycoplasma pneumonia pneumonia. J Trop Pediatr 2016;63(4):1-7.Search in Google Scholar

25. Xu X, Li X, Liu J, Wu L, Chen Z. Serum cytokine profile contributes to discriminating M. pneumoniae pneumonia in children. Cytokine 2016;86:73-78. DOI: 10.1016/j.cyto.2016.07.01810.1016/j.cyto.2016.07.01827475111Open DOISearch in Google Scholar

26. Chaudhry H, Zhou J, Zhong Y, Ali MM, McGuire F, Nagarkatti P, et al. Role of cytokines as a double-edged sword in sepsis. In Vivo 2015;27(6):669-84.Search in Google Scholar

27. Kurata S, Osaki T, Yonezawa H, Arae K, Taguchi H, Kamiya S. Role IL-17A and IL-10 in the antigen induced inflammation model by Mycoplasma pneumoniae. BMC Microbiol 2014;14(1): 156. DOI: 10.1186/1471-2180-14-15610.1186/1471-2180-14-156407413924928272Search in Google Scholar

28. Paats M, Bergen I, Hanselaar W, van Zoelen E, Verbrugh H, Hoogsteden H, et al. T helper 17 cells are involved in the local and systemic inflammatory response in community-acquired pneumonia. Thorax 2013;68(5):468-474. DOI: 10.1136/thoraxjnl-2012-20216810.1136/thoraxjnl-2012-20216823315492Open DOISearch in Google Scholar

29. Higa F, Haroon A, Iha Y, Tasato D, Nakamura H, Kinjo T, et al. Interleukin-17A in Legionella pneumonia: A Retrospective Study. Jpn J Infect Dis 2015;68(2):148-150. DOI: 10.7883/yoken.JJID.2014.17110.7883/yoken.JJID.2014.17125672354Open DOISearch in Google Scholar

30. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy MD, Fine J, et al. Understanding the Inflammatory Cytokine Response in Pneumonia and Sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007;167(15):1655-63. DOI: 10.1001/archinte.167.15.165510.1001/archinte.167.15.1655449565217698689Open DOISearch in Google Scholar

31. Marti C, Garin N, Grosgurin O, Poncet A, Combescure C, Carballo S, et al. Prediction of severe community-acquired pneumonia : a systematic review and meta-analysis. Crit Care 2012;16(4):R141. DOI: 10.1186/cc1144710.1186/cc11447358072722839689Open DOISearch in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo